Adding Pembrolizumab to Trastuzumab and Chemotherapy Prolongs OS in First-Line Treatment for Unresectable or Metastatic HER2-positive Gastric/GEJ Adenocarcinoma
Results of the final analysis of overall survival in the KEYNOTE-811 study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1551 results
FDA Approves Isatuximab-irfc with Bortezomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma
Evidence for efficacy is based on the results from the IMROZ study
EMA Recommends Granting a Marketing Authorisation for Serplulimab
It is intended in combination with carboplatin and etoposide for the first-line treatment of adult patients with ES-SCLC
Targeted Therapy, Driven by Comprehensive Genomic Profiling and Molecular Tumour Board, Improves Outcomes In Pretreated Patients with Metastatic Cancer
Findings from the ROME study
Trastuzumab Deruxtecan Prolongs PFS After Endocrine-Based Therapy in Patients with HR-positive, HER2-low or HER2-ultralow Metastatic Breast Cancer
Findings from the DESTINY-Breast06 study
Insights Into the Biology of Response and Resistance to MAPK Pathway Targeted Therapy in Patients with BRAFV600E-mutated mCRC
Findings from prespecified, exploratory biomarker analysis of BEACON CRC study
FDA Approves Neoadjuvant/Adjuvant Nivolumab for Resectable Non-Small Cell Lung Cancer
Evidence for efficacy is based on the results from the CHECKMATE-77T study
EMA Recommends Extension of Therapeutic Indications for Daratumumab
New indication concerns a combination with bortezomib, lenalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant
Pembrolizumab Plus Chemoradiotherapy Significantly Improves OS in Patients with Locally Advanced Cervical Cancer
Overall survival results from the second interim analysis of the ENGOT-cx11/GOG-3047/KEYNOTE-A18 study
10-Year Data Underscore How ICI Therapy Has Helped to Change the Long-Term Prognosis for Patients with Advanced Melanoma
Final results from the CheckMate 067 study
Efficacy of Tivozanib Monotherapy in the Post-ICI Setting Among Patients with Advanced Renal Cell Cancer
Findings from the TiNivo-2 study
FDA Approves Osimertinib for Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer Following Chemoradiation Therapy
Evidence for efficacy is based on the results from the LAURA study